Fluticasone Propionate
Brand names: Flovent Hfa, Fluticasone Propionate, Fluticasone Propionate Hfa, Flovent Diskus, Xhance
At a glance
- Medicare prescriptions, 2024
- 12,017,747
- Medicare drug cost
- $213.2M
- Average cost per prescription
- $17.74
- Clinicians who prescribed it
- 221,859
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Fluticasone Propionate HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older.
From the FDA-approved prescribing information (label dated January 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 31.1%
- Internal Medicine 23.0%
- Nurse Practitioners 20.6%
- Physician Assistants 8.0%
- ENT (Otolaryngology) 5.3%
- Pulmonology 3.7%
- Allergy & Immunology 1.9%
- General Practice 1.6%
- Geriatric Medicine 1.0%
- Facial Plastic Surgery 0.8%
- Critical Care Medicine 0.3%
- Emergency Medicine 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 1% from 2019 to 2024.
Biggest change by state since 2019
- Kentucky +13%
- Louisiana +13%
- Puerto Rico +11%
- Hawaii +10%
- Indiana +9%
- Massachusetts (smallest change) −19%
- Washington (smallest change) −17%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cvs Woonsocket Prescription Center, Incorporated
| Strength | Looks like | Imprint |
|---|---|---|
| 50 ug | white spray | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $944,970 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Optinose US, Inc. $884,699
- Paratek Pharmaceuticals, Inc. $60,272
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.